Nanjing Pharmaceutical
Nanjing Pharmaceutical, also known as Nanjing Pharmaceutical Company Limited, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across Asia and expanding into international markets, Nanjing Pharmaceutical is recognised for its commitment to quality and innovation. The company’s core offerings include generic medications and specialty pharmaceuticals, distinguished by their rigorous adherence to international standards and advanced production techniques. Nanjing Pharmaceutical has achieved notable milestones, positioning itself as a trusted name in the industry, with a focus on enhancing healthcare solutions globally. Its dedication to research and development continues to drive its success in a competitive market.
DitchCarbon Score
How does Nanjing Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nanjing Pharmaceutical's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nanjing Pharmaceutical's reported carbon emissions
In 2022, Nanjing Pharmaceutical reported an exhaust emissions intensity of approximately 0.0896 kg CO2e per unit of revenue, with total revenue of about USD 7.28 billion. The previous year, 2021, the emissions intensity was about 0.0762 kg CO2e per unit of revenue, indicating a slight increase in emissions relative to revenue. The company has not disclosed specific Scope 1, 2, or 3 emissions data, nor has it set any formal reduction targets or climate pledges. Nanjing Pharmaceutical's emissions data is not cascaded from a parent company, and there are no reported initiatives under the Science Based Targets initiative (SBTi) or other climate commitments. The company appears to be in the early stages of addressing its carbon footprint, with no significant reduction initiatives currently documented. Overall, while Nanjing Pharmaceutical has reported emissions intensity figures, it lacks comprehensive emissions data and formal climate commitments, highlighting an opportunity for future improvement in sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nanjing Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
